n (%) | ITIP1 N = 21 | ITIP2 N = 49 | ITIP3 N = 13 | Total N = 83 | p-value |
---|---|---|---|---|---|
CXR findings | 0.008 | ||||
CXR with no significant pathology | 9 (42.9) | 21 (42.9) | 1 (7.7) | 31 (37.3) | |
CXR with significant pathology | 12 (57.1) | 28 (57.1) | 12 (92.3) | 52 (62.7) | |
Primary endpoint pneumoniaa | 2 (16.7) | 8 (28.6) | 8 (66.7) | 18 (34.6) | |
Other infiltrates only | 10 (83.3) | 20 (71.4) | 4 (33.3) | 34 (65.4) | |
Pleural effusion | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
Clinical diagnoses at time of CXR | 0.006 | ||||
Fast-breathing pneumonia | 3 (14.3) | 7 (14.3) | 0 (0.0) | 10 (12.0) | |
Chest-indrawing pneumonia | 5 (23.8) | 22 (44.9) | 4 (30.8) | 31 (37.4) | |
Danger sign pneumonia | 3 (14.3) | 15 (30.6) | 7 (53.8) | 25 (30.1) | |
Otherb | 10 (47.6) | 5 (10.2) | 2 (15.4) | 17 (20.5) | |
CXR indications | 0.001 | ||||
First-line intravenous antibiotic treatment failure | 4 (19.0) | 17 (34.7) | 3 (23.1) | 24 (28.9) | |
Isolated fever | 9 (42.9) | 1 (2.0) | 1 (7.7) | 11 (13.3) | |
Treatment failure/relapse at Day 14 | 5 (23.8) | 24 (49.0) | 6 (46.2) | 35 (42.2) | |
Otherc | 3 (14.3) | 7 (14.3) | 3 (23.1) | 13 (15.7) |